Parker Hannifin — a diversified manufacturer of motion and control technologies and systems — has announced the creation of a new division, Parker Bioscience.
The division, which has sites in Birtley, UK and Oxnard, California, will deliver international bioprocessing, food and beverage, and healthcare solutions, which previously were operated under the Parker domnick hunter brand.
Parker Bioscience designs, supplies, and delivers whole systems for both upstream and downstream pharmaceutical and biopharmaceutical manufacturing, and provides filtration solutions for the global food and beverage industry.
Parker Bioscience provides integrated bioprocessing solutions that speed up development times, increase efficiency and safety, and enable reproducible quality. Incorporating SciLog and domnick hunter, Parker Bioscience combines filtration, single-use fluid-handling systems, and sensors into automated single-use solutions.
The new division will also build on Parker domnick hunter’s heritage in the food and beverage sector, for which it provides a wide range of filtration solutions. Parker Bioscience has specialist expertise in the brewing, bottled water, wine and dairy industries, and supports companies in improving process control, efficiency and security throughout their production and packaging processes.
The launch of the new division coincides with increased investment by Parker Hannifin in its Birtley, UK site. Earlier this year, the company announced that the facility was to start to manufacture the company’s automated bioprocessing systems, complementing existing production at its site in Oxnard, California, while 2016 saw the introduction of a new ISO Class 7 clean room at the facility, from which Parker Bioscience is now producing single-use manifolds incorporating tubing, bioprocess containers, filters, sensors, and other components for use in the bioprocessing industry.
This additional manufacturing capability will allow the newly named Parker Bioscience to service its European biopharmaceutical markets more effectively, shortening the supply chain and making it easier for biopharmaceutical manufacturers to access automated systems, manifolds and receive close specialist technical support.
The investment also means that Parker Bioscience can offer a more robust manufacturing capacity, based around the capabilities of its dual sites, an important capability for business continuity planning.
“The launch of Parker Bioscience demonstrates Parker Hannifin’s strong ongoing commitment to its clients in the biopharmaceutical manufacturing and food and beverage sectors,” Kris Holmes, business unit manager at Parker Bioscience, said. “In conjunction with increased investment in the Birtley site, this is a major step forward for our operations in the UK and further enhances our ability to serve European markets.”
(Source: Parker Hannifin)
Filed Under: Drug Discovery
